{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Malignant+Neoplasm+in+the+Lung&page=2",
    "query": {
      "condition": "Metastatic Malignant Neoplasm in the Lung",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Malignant+Neoplasm+in+the+Lung&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:05:53.456Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00054795",
      "title": "Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Brain Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Metastases, Neoplasm"
      ],
      "interventions": [
        {
          "name": "Motexafin Gadolinium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharmacyclics LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 550,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-05-08",
      "last_synced_at": "2026-05-22T04:05:53.456Z",
      "location_count": 44,
      "location_summary": "Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 41 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00054795"
    },
    {
      "nct_id": "NCT05753722",
      "title": "A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors",
        "Non Small Cell Lung Cancer",
        "NSCLC"
      ],
      "interventions": [
        {
          "name": "PRTH-101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Incendia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 270,
      "start_date": "2023-03-03",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-05-22T04:05:53.456Z",
      "location_count": 11,
      "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05753722"
    },
    {
      "nct_id": "NCT05802186",
      "title": "Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lung Carcinoma",
        "Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Neoplasm in the Lung",
        "Stage I Lung Cancer AJCC v8",
        "Stage II Lung Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Radiology, Treatment Planning",
          "type": "OTHER"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2023-11-20",
      "completion_date": "2031-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-05-22T04:05:53.456Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05802186"
    },
    {
      "nct_id": "NCT06051695",
      "title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Colorectal Cancer",
        "NSCLC",
        "Non Small Cell Lung Cancer",
        "NSCLC, Recurrent",
        "Non-Small Cell Squamous Lung Cancer",
        "Pancreas Cancer",
        "Pancreatic Neoplasm",
        "Colorectal Adenocarcinoma",
        "CRC",
        "Colon Cancer",
        "Rectal Cancer",
        "Cancer",
        "Ovarian Cancer",
        "Ovarian Neoplasms",
        "Mesothelioma",
        "Mesothelioma, Malignant",
        "Ovary Cancer",
        "Lung Cancer",
        "MESOM"
      ],
      "interventions": [
        {
          "name": "A2B694",
          "type": "BIOLOGICAL"
        },
        {
          "name": "A2B543",
          "type": "BIOLOGICAL"
        },
        {
          "name": "xT CDx with HLA-LOH Assay",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "A2 Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 474,
      "start_date": "2024-04-03",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-05-22T04:05:53.456Z",
      "location_count": 12,
      "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06051695"
    },
    {
      "nct_id": "NCT00003046",
      "title": "Interleukin-12 in Treating Patients With Cancer in the Abdomen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anal Cancer",
        "Colorectal Cancer",
        "Gallbladder Cancer",
        "Gastric Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Recombinant Interleukin-12",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "1997-08",
      "completion_date": "2001-10",
      "has_results": false,
      "last_update_posted_date": "2012-07-30",
      "last_synced_at": "2026-05-22T04:05:53.456Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003046"
    },
    {
      "nct_id": "NCT03849469",
      "title": "A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Cervical Carcinoma",
        "Pancreatic Carcinoma",
        "Triple Negative Breast Cancer",
        "Hepatocellular Carcinoma",
        "Urothelial Carcinoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Nasopharyngeal Carcinoma",
        "Renal Cell Carcinoma",
        "Non-small Cell Lung Carcinoma",
        "Small Cell Lung Carcinoma",
        "Gastric or Gastroesophageal Junction Adenocarcinoma",
        "Advanced or Metastatic Solid Tumors",
        "Prostate Carcinoma",
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma",
        "Intrahepatic Cholangiocarcinoma",
        "Squamous Cell Anal Cancer",
        "Squamous Cell Penile Carcinoma",
        "Squamous Cell Vulvar Carcinoma",
        "Colorectal Carcinoma",
        "Endometrial Carcinoma"
      ],
      "interventions": [
        {
          "name": "XmAb®22841",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab (Keytruda®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2019-05-29",
      "completion_date": "2023-02-16",
      "has_results": false,
      "last_update_posted_date": "2023-03-30",
      "last_synced_at": "2026-05-22T04:05:53.456Z",
      "location_count": 28,
      "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03849469"
    },
    {
      "nct_id": "NCT06315296",
      "title": "An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Metastatic Breast Carcinoma",
        "Metastatic Lung Carcinoma",
        "Metastatic Malignant Neoplasm in the Brain",
        "Stage IV Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Behavioral Dietary Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Text Message-Based Navigation Intervention",
          "type": "OTHER"
        },
        {
          "name": "Internet-Based Intervention",
          "type": "OTHER"
        },
        {
          "name": "Dietary Counseling and Surveillance",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Stereotactic Radiosurgery",
          "type": "RADIATION"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Neurocognitive Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Interview",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2023-12-13",
      "completion_date": "2025-10-29",
      "has_results": false,
      "last_update_posted_date": "2026-03-03",
      "last_synced_at": "2026-05-22T04:05:53.456Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06315296"
    },
    {
      "nct_id": "NCT02903914",
      "title": "Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Cancer",
        "Solid Tumors",
        "Colorectal Cancer (CRC)",
        "Gastric Cancer",
        "Head and Neck Cancer",
        "Lung Cancer",
        "Renal Cell Carcinoma (RCC)",
        "Bladder Cancer",
        "UC (Urothelial Cancer)",
        "Mesothelioma"
      ],
      "interventions": [
        {
          "name": "INCB001158",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 260,
      "start_date": "2016-09-14",
      "completion_date": "2022-08-15",
      "has_results": true,
      "last_update_posted_date": "2025-08-05",
      "last_synced_at": "2026-05-22T04:05:53.456Z",
      "location_count": 13,
      "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02903914"
    },
    {
      "nct_id": "NCT05827614",
      "title": "Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple Negative Breast Cancer (TNBC)",
        "High Grade Serous Ovarian Carcinoma",
        "High Grade Endometrial Carcinoma",
        "Anogenital Cancer",
        "Head and Neck (HNSCC)",
        "Cutaneous Squamous Cell Carcinoma (CSCC)",
        "Cervical Squamous Cell Carcinoma",
        "ER+ Breast Cancer",
        "Leiomyosarcoma (LMS)",
        "Undifferentiated Pleomorphic Sarcoma (UPS)",
        "Pancreatic Cancer Metastatic",
        "Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "BBI-355",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Futibatinib",
          "type": "DRUG"
        },
        {
          "name": "BBI-825",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boundless Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2023-03-24",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-05-22T04:05:53.456Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Santa Monica, California • Denver, Colorado + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05827614"
    },
    {
      "nct_id": "NCT05948865",
      "title": "A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Cancer, Lung"
      ],
      "interventions": [
        {
          "name": "CPO301",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Conjupro Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2023-06-06",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-03-20",
      "last_synced_at": "2026-05-22T04:05:53.456Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Newport Beach, California • Santa Monica, California + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05948865"
    }
  ]
}